KASSEL, Germany, June 6, 2013 /PRNewswire/ -- Biozoom (OTC QB:
BIZM), creator of the world's first portable, handheld device for
real-time biofeedback, announced today that Dr. Jurgen Lademann, has accepted an appointment as
Chairman of the Biozoom Scientific Advisory Board. "We are pleased
and honored that a scholar of Dr. Lademann's caliber and
intellect will be advising the technological evolution of Biozoom,
said CEO Hardy Hoheisel. "As
Director of Charite Berlin's Center
of Experimental and Applied Cutaneous Physiology Dr. Lademann has
seen firsthand the remarkable benefits Biozoom can have not only in
research, but on improving the health and wellness of people's
lives."
An internationally recognized researcher of the connections
among dermatology, pharmacology and biophysics, Dr. Lademann is one
of the leading experts on non-invasive measurement of biomarkers in
human skin. Dr. Lademann has tested and used the Biozoom scanner
for more than five years. "Biozoom's support of and cooperation
with the Center has been invaluable. After we validated its
reliability in the lab, our studies have proved its effectiveness
in the field. We have used it to advance our scientific work,
helping us to clarify the physiological function of antioxidants in
the skin. The scanner has generated a great deal of interest
wherever it has been used, and I receive inquiries about it almost
every day, it seems."
Dr. Lademann studied at the Martin-Luther University, Halle, and
Moscov-Lomonosov University, after which he was appointed Group and
Project Manager at the Institute of Optics and Spectroscopy of the
Academy of Science. Since 1998 he has been Head of the Center of
Experimental and Applied Cutaneous Physiology, Department of
Dermatology, Charite - Berlin. In 2000, he was appointed
Professor of Dermatology at Charite - Universitatsmedizin Berlin.
He is the editor of the international journal "Skin Pharmacology
and Applied Skin Physiology" and board member of the German Federal
Institute of Risk Assessment, Berlin,
Germany. Dr. Lademann is also the President of the
"International Society of Skin Pharmacology and Physiology" and
Member of the Experts Team for Risk Assessment of Nanoparticles in
Cosmetic Products with ECETOC AISBL, Brussels.
"I look forward to helping guide the development of new
capabilities and applications for hand held reflective
spectroscopy," said Dr. Lademann. "The potential for widespread
adoption of Biozoom's product is great."
About Biozoom
Biozoom is an innovative technology
development company, specializing in the commercialization of our
advances in mobile spectroscopy. Our intellectual property
portfolio and ongoing research are positioned to apply Biozoom's
technology breakthroughs to a wide range of markets. Our first
consumer product, the Biozoom scanner, gives people the feedback
they need to manage their health, wellness and fitness on
demand. Tested in leading health institutions, our
scanner is the first of its kind—a handheld, transdermal
device for measuring biomarkers, including antioxidant levels, at
the click of a button. Scan results— and customized wellness
coaching based on those biomarkers— are sent instantly to a
smartphone or online account. The scanner will enable leaders
in the health and wellness industry to create new levels of
customer loyalty and revenues as a result. For more information,
visit www.biozoom.net.
Disclaimer
This press release contains
"forward-looking statements". Statements in this press release
which are not purely historical are forward-looking statements and
include any statements regarding beliefs, plans, expectations or
intentions regarding the future, and specifically references to
future potential purchase orders and re-orders from consumers and
distributors. The reader can identify these forward-looking
statements by forward-looking words such as "may," "will,"
"expect," "potential," "anticipate," "forecast," "believe,"
"estimate," "project," "plan," "continue" or similar words. The
reader should read statements that contain these words carefully
because they discuss future expectations, contain projections of
future results of operations or of financial condition, or state
other forward-looking information. Forward-looking statements
include, but are not limited to, statements regarding potential
products, customers, revenues, expansion efforts, and future plans
and objectives of Biozoom, Inc. ("Biozoom"). The risk factors
listed in our disclosure documents and the cautionary language
therein provide examples of risks, uncertainties and events that
may cause actual results to differ materially from the expectations
and projections described by Biozoom in its forward-looking
statements. Actual results relating to, among other things, product
launch, sales, customer acceptance and market share could differ
materially from those currently anticipated in such statements.
Factors affecting forward-looking statements include: consumer
preferences, competition from more established brands, ability to
develop market share; changes in the operating costs; changes in
economic conditions, foreign exchange and other financial markets;
changes of the interest rates on borrowings; changes in the
investments levels; litigation; legislation; environmental,
judicial, regulatory, political and competitive developments in
areas in which Biozoom operates; technological, mechanical and
operational difficulties encountered in connection with Biozoom's
development activities; and labor relation matters and costs. The
reader should refer to the risk disclosures set out in the periodic
reports and other disclosure documents filed by Biozoom from time
to time with the Securities and Exchange Commission and other
regulatory authorities.
SOURCE Biozoom